<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976231</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00108243</org_study_id>
    <nct_id>NCT04976231</nct_id>
  </id_info>
  <brief_title>MPS II Immunophenotyping</brief_title>
  <official_title>Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how participant's body's immune system responds&#xD;
      to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells&#xD;
      are involved in causing untoward responses to the ERT so that the investigators can relate&#xD;
      the level of immune response to the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the frequency of natural killer cells measured by flow cytometry</measure>
    <time_frame>baseline, 1, 3, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in level of circulation memory B cells measured by flow cytometry</measure>
    <time_frame>baseline, 1, 3, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in level of T follicular helper cells measured by flow cytometry</measure>
    <time_frame>baseline, 1, 3, 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in distribution of helper T cells measured by flow cytometry</measure>
    <time_frame>baseline, 1, 3, 6 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>MPS II</condition>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>Hunter Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment Naive</arm_group_label>
    <description>subjects who are na√Øve to ERT and start treatment with idursulfase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment less than 3 years</arm_group_label>
    <description>Subjects who have received ERT for &lt;3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment over 3 years</arm_group_label>
    <description>Subjects who have received ERT for 3 or more years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Metabolic or Genetics Clinic patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a confirmed diagnosis of Mucopolysaccharidosis type II (MPS II) or Hunter&#xD;
             Syndrome based on enzyme activity and variant analysis.&#xD;
&#xD;
          -  Subject who plan to receive or have received enzyme replacement therapy with&#xD;
             idursulfase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Priya Kishnani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Workman</last_name>
    <phone>919 660-0758</phone>
    <email>lauren.workman@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ankit Desai, MD</last_name>
    <phone>919-613-6310</phone>
    <email>ankit.desai@duke.edu</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS II</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Hunter Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

